Between Visits Adjusted for Multiple Comparisons in a Generalized Linear Mixed Model. Analysis is based on the 9 subjects completing the trial; Data is adjusted for baseline severity (using random intercept in the mixed model linear regression analysis) and the duration of disease for each subject (Visit 0 = baseline; Visit 1 = pre-placebo treatment; Visit 2 = post-placebo/pre-benralizumab visit; Visits 2-4 = Benralizumab 30 mg s.c. treatment;Visit 5 = 4 week post-Benralizumab visit (determination of primary efficacy end-point); Visit 6 = 8 week post-benralizumab follow-up visit (determination of long term efficacy and adverse events); *primary and exploratory outcomes are shaded (Adj p <.05).
Table 2. Differences in Relative Eosinophil Counts (Eos%) Between Visits in CSU Subjects Before and After Treatment with Benralizumab